Background Advances in interventional techniques now allow for transcatheter treatment of
some ventricular septal defects (VSD), although there remain concerns about adverse …

Congenital heart disease (CHD) is one of the most common inborn defects, occurring in
approximately 0.8% of newborn infants. 75 98 The frequency of the common congenital …

Aim To report the experience of 23 tertiary referral European Centres on transcatheter
closure of congenital ventricular septal defects (VSD). Methods and results Implantation of …

Objectives: We sought to analyze safety, efficacy, and follow-up results of percutaneous
closure of perimembranous ventricular septal defects (pmVSD). Background: Results of …

Objectives: This phase I study attempted to report the initial safety and efficacy results of
transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using the new …

Objective: To report the immediate and midterm results of transcatheter closure of
perimembranous ventricular septal defect (PmVSD) using the Amplatzer membranous VSD …

Background While transcatheter device closure of ventricular septal defects (VSDs) is
gaining popularity, concerns remain about adverse events; particularly heart block in peri …

OBJECTIVE: The development of the Amplatzer Membranous VSD Occluder (AGA Medical
Corp, Plymouth, Minn) for closure of the perimembranous ventricular septal defect has …

This study reports on experience with transcatheter closure of congenital ventricular septal
defects (VSDs) with Amplatzer septal occluders. From January 2000 to April 2005 …

Aims The aim of this study was to evaluate the safety and efficacy of transcatheter closure for
perimembranous ventricular septal defect (pmVSD) and its long-term results. The most …